Discover how the S&P 500 Index performed in 2024 and what that could mean for the first quarter of 2025 according to Barclays ...

Investment firm Barclays laid out its thoughts for the technology space in 2025 in a research note on Thursday, covering ...

Barclays Plc’s Stephen Dainton is preparing for a wave of dealmaking this year as more US companies have been buoyed by ...

Barclays PLC BARC shares inched down 0.26% to £2.65 Wednesday, on what proved to be an all-around positive trading session ...

Emmanuel Cau, head of European equity strategy at Barclays, weighs in on the outlook for European stocks in 2025.

Barclays PLC BARC shares slid 2.60% to £2.66 Tuesday, on what proved to be an all-around grim trading session for the stock ...

From China to Europe, Canada to Mexico, world markets are already reeling from Donald Trump's promise to jack up tariffs when ...

China, the global growth engine for the last 20 years, now boasts lower long-term bond yields than Japan, the former poster ...

Simple volatility is the biggest risk for retail investors. Crypto coins, tokens, and currencies are “purely speculative,” ...

Financial analysts at Barclays have upgraded Boeing (BA) to Overweight, citing improved balance sheet, higher free cash flow, ...

First Abu Dhabi Bank PJSC, Barclays Plc, Mashreqbank PSC and Standard Chartered Plc are among the lenders in discussion with ...

Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.